Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multicenter, Randomized, Placebo-Controlled, Double-Blinded Pivotal Study To Evaluate Safety And Immunogenicity Of A Live-Attenuated Chikungunya Virus Vaccine Candidate In Adults Aged 18 Years And Above

Next Previous
Trial Profile

A Multicenter, Randomized, Placebo-Controlled, Double-Blinded Pivotal Study To Evaluate Safety And Immunogenicity Of A Live-Attenuated Chikungunya Virus Vaccine Candidate In Adults Aged 18 Years And Above

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 09 Feb 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs VLA 1553 (Primary)
  • Indications Chikungunya virus infections
  • Focus Adverse reactions; Pharmacodynamics; Registrational
  • Sponsors Valneva

Most Recent Events

  • 19 Jan 2026 According to a Valneva media release, the company has decided to voluntarily withdraw its Biologics License Application (BLA) for VLA1553. This decision follows the U.S. FDA's suspension of the license in August 2025.
  • 05 Feb 2025 According to a Valneva media release, company expects to receive marketing approval in Brazil in the first quarter of 2025, which would represent the first approval in an endemic country.
  • 05 Feb 2025 According to a Valneva media release, company announced that the Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorization in the United Kingdom (UK) for the world's first and only chikungunya vaccine, IXCHIQ based on the data of this study.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top